The ‘Normal’ Hemoglobin That’s Failing Your Heart

Key Takeaway: A major pooled analysis of over 42,000 heart failure patients has revealed that the lowest risk of death or hospitalization occurs at hemoglobin levels of approximately 14 g/dL for women and 15 g/dL for men. These values are significantly higher than the World Health Organization’s thresholds for anemia, suggesting that many heart failure patients currently labeled as ‘non-anemic’ may actually be at increased risk.

A Number That Should Unsettle Every Cardiologist

Imagine a 68-year-old female patient with heart failure whose routine blood work shows a hemoglobin level of 12.5 g/dL. By all textbook definitions, this patient is not anemic. The lab report likely flags the result in reassuring black letters—no red warning, no asterisk. Her physician glances at the number, nods, and moves on to the echocardiogram report. But what if this “normal” hemoglobin value is silently contributing to her risk of death or rehospitalization? A comprehensive new analysis suggests just that, challenging one of clinical medicine’s most established reference ranges.

What Did the Researchers Do?

This was not a single study but a pooled analysis of patient-level data from 11 major clinical trials in heart failure. The dataset encompassed the full spectrum of the condition, including over 42,000 patients with heart failure with reduced ejection fraction (HFrEF), preserved ejection fraction (HFpEF), and the intermediate category known as mildly reduced ejection fraction (HFmrEF). By combining individual patient data rather than just published results, the researchers were able to examine the relationship between hemoglobin concentration and outcomes—specifically death and hospitalization for heart failure—with extraordinary precision and statistical power^[1].

The Findings

The results were striking in their clarity. For the composite endpoint of death or hospitalization for heart failure, the lowest risk was observed at hemoglobin levels of approximately 14 g/dL in women and 15 g/dL in men. These optimal values were a full 2 g/dL above the long-accepted World Health Organization (WHO) thresholds for anemia—12 g/dL for women and 13 g/dL for men^[2]. Even patients in the “low-normal” range, with hemoglobin just 0 to 1 g/dL above the WHO cutoff, carried a higher risk than those with hemoglobin 2 g/dL or more above the threshold. Critically, these findings held true regardless of ejection fraction, meaning the pattern was not confined to a single subtype of heart failure.

The Mechanism: Why a Failing Heart Demands More

To understand why this matters, one must consider what hemoglobin actually does. Each hemoglobin molecule is an oxygen carrier, binding oxygen in the lungs and releasing it in peripheral tissues. In a healthy person, the body maintains a comfortable margin of hemoglobin, sufficient to meet oxygen demand even during exertion. But heart failure fundamentally changes this equation.

A failing heart is already struggling to maintain adequate cardiac output. All the body’s tissues—skeletal muscle, kidneys, gut—exist in a state of relative oxygen deprivation^[3]. When hemoglobin drops even modestly, the oxygen-carrying capacity of each unit of blood decreases. The heart tries to compensate by pumping harder and faster, which increases wall stress and myocardial oxygen consumption, creating a vicious cycle that accelerates disease progression^[4].

Compounding the problem is iron deficiency, which is present in about 50% of heart failure patients, regardless of whether they meet formal criteria for anemia^[5]. Iron is not only essential for hemoglobin synthesis; it also plays a direct role in mitochondrial energy production within the heart’s own muscle cells, the cardiomyocytes. Depleted iron stores impair both oxygen delivery and the cellular machinery needed to use that oxygen efficiently. This double blow helps explain why even “borderline” hemoglobin levels can have outsized consequences in heart failure and why intravenous iron supplementation has shown benefits in randomized trials, even in non-anemic heart failure patients^[6].

There is also the neurohormonal dimension. Low hemoglobin, and therefore hypoxia, triggers neurohormonal activation, stimulating erythropoietin production by the kidneys. It also activates the sympathetic nervous system and the renin-angiotensin-aldosterone system—the very pathways that heart failure therapies are designed to suppress^[7]. In effect, a hemoglobin level that might be entirely benign in a healthy individual can become a metabolic and neurohormonal accelerant in the context of heart failure.

Notable Limitations

Despite its scale, this analysis has important limitations. Its design is observational; the researchers have identified an association between hemoglobin levels and outcomes, but they cannot prove that raising hemoglobin to the “optimal” range would reduce risk. Past attempts to raise hemoglobin using erythropoiesis-stimulating agents in heart failure and chronic kidney disease have yielded disappointing and sometimes harmful results^[8], underscoring that the relationship is more complex than simply pushing numbers up. The pooled trials also varied in their patient populations, follow-up durations, and background therapies, which could introduce heterogeneity. And while the findings span the ejection fraction spectrum, the bulk of available trial data still skews toward HFrEF.

Conclusion: Rethinking ‘Normal’ in Clinical Practice

For patients living with heart failure, this analysis carries a practical message: a hemoglobin value that falls within the “normal” range on a standard lab report may not be normal for you. The data suggest the threshold for clinical concern should be higher—closer to 14 g/dL for women and 15 g/dL for men—and that a hemoglobin of 12.5 g/dL in a woman with heart failure should not be dismissed as insignificant.

What does this mean in practice? It means that iron studies—ferritin and transferrin saturation—deserve a place in the routine workup of every heart failure patient, not just those who meet the WHO definition of anemia. It means that treatable causes of low hemoglobin, from iron deficiency to occult blood loss, should be investigated more aggressively. And it may mean that the habit of glancing at a hemoglobin result, seeing it’s above 12 or 13, and moving on needs to end. The failing heart is telling us it needs more. This analysis suggests we should listen.

Of course, I want to emphasize another point here. What happens if no underlying disease causing low hemoglobin is found? The dangers of administering unnecessary iron are also clear. Furthermore, what should be done in countries like ours where thalassemia trait is common? A large proportion of these individuals have hemoglobin levels at or slightly below the lower limit of normal. This study leaves many questions unanswered that require further investigation. In conclusion, my understanding from this study is that if anemia is identified in a patient with heart failure and its cause is determined, it must be treated.

Scientific Sources

1. Chimura M, et al. Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure. Journal of the American College of Cardiology. 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42663359/
2. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. WHO. 2011.
3. Poole DC, et al. Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance. Am J Physiol Heart Circ Physiol. 2012. DOI: 10.1152/ajpheart.00943.2011
4. Anand IS, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004. DOI: 10.1161/01.CIR.0000134279.79571.73
5. Klip IT, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013.
6. DOI: 10.1016/j.ahj.2013.01.017
7. Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009. DOI: 10.1056/NEJMoa0908355
8. Silverberg DS, et al. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol. 2006. DOI: 10.1016/j.semnephrol.2006.05.006
9. Swedberg K, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013. DOI: 10.1056/NEJMoa1214865